Ansel P. Nalin

Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Xiaowen Tang, Lin Yang, Zheng Li et al. · PubMed · 2018 · 412 citations · Full text

Medicine, Hematology, Immunology +17

The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector

Wenjuan Dong, Xiaojin Wu, Shoubao Ma et al. · Cancer Discovery · 2019 · 307 citations · Full text

Life Sciences, Immunology, Oncology +17

CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway

Luxi Chen, Youssef Youssef, Cameron Robinson et al. · Immunity · 2018 · 115 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

The IL-15–AKT–XBP1s signaling pathway contributes to effector functions and survival in human NK cells

Yufeng Wang, Yibo Zhang, Ping Yi et al. · Nature Immunology · 2018 · 113 citations

Life Sciences, Cell Biology, Immunology +11

IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-κB

Aaron Victor, Ansel P. Nalin, Wenjuan Dong et al. · The Journal of Immunology · 2017 · 97 citations · Full text

Life Sciences, Immunology, Microbiology +17